Trial Profile
A Multi-Center Randomized Phase III Study Evaluating 4 Cycles of Docetaxel, Doxorubicin and Cyclophosphamide Versus 4 Cycles of Vinorelbine and Capecitabine in Patients Not Sufficiently Responding to 2 Cycles of TAC and 4 Cycles of TAC Versus 6 Cycles of TAC in Patients Sufficiently Responding to 2 Cycles of TAC as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Doxorubicin (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer; Early breast cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms GeparTrio
- 14 Dec 2019 Results (N= 15,457), a metanalysis of prospective randomized trials assessing efficacy of Capecitabine as a part of neo adjuvant or adjuvant therapy in patients with early breast cancer, presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 20 Apr 2016 Results (pooled analysis of this and other study) assessing genomic alterations in pretherapeutic core biopsies presented at the 107th Annual Meeting of the American Association for Cancer Research.
- 10 Dec 2011 Results presented at the 34th Annual San Antonio Breast Cancer Symposium.